Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428364 | 0.78 | GRIN2D (0.53) | TRPV1MAPK3 | |
| SCHEMBL4357920 | 0.78 | TRPV1 (0.54) | TRPV1ALDH1A1 | |
| SCHEMBL14427314 | 0.76 | TRPV1 (0.50) | TRPV1MAPK3 | |
| SCHEMBL30611217 | 0.73 | ALDH1A1 (0.41) | ALDH1A1POLBHPGD | |
| SCHEMBL29110299 | 0.73 | ALDH1A1 (0.41) | ALDH1A1POLBHPGD | |
| SCHEMBL30575356 | 0.72 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL2294638 | 0.72 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL14430632 | 0.70 | TRPV1 (0.51) | TRPV1MAPK3 | |
| SCHEMBL4682233 | 0.69 | TRPV1 (0.50) | TRPV1MAPK3ALDH1A1 | |
| SCHEMBL4360051 | 0.69 | TRPV1 (0.44) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070203133-A1 | Substituted 5,12-diaza-benzoanthracene analogues | NEUROGEN CORPORATION (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1723145-A2 | SUBSTITUTED 5,12-DIAZA-BENZOANTHRACENE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005086968-A2 | SUBSTITUTED 5,12-DIAZA-BENZOANTHRACENE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203133-A1 | Substituted 5,12-diaza-benzoanthracene analogues | GPR52, SUCNR1, MC1R | TRPV1 246/4885MAPK3 3743/4885ALDH1A1 613/4885 |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | TRPV1 279/4885MAPK3 3351/4885ALDH1A1 2412/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | TRPV1 281/4885MAPK3 3441/4885ALDH1A1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.